All In Biotech

Drug Trial Radar · NCT07747090

A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.

A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of FXS6837 Versus Eculizumab in Complement Inhibitor-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Dec 10, 2026

Primary completion

May 5, 2028

Study completion Jul 31, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label study to evaluate the efficacy and safety of FXS6837 capsules compared to eculizumab in naive PNH patients. About 90 PNH patients who are naive to complement inhibitor therapies will be enrolled to take FXS6837 capsules or eculizumab for 24 weeks according to protocol.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • FXS6837 CapsuleDrug

    FXS6837 capsule orally taken for 24 weeks

  • Eculizumab infusionBiological

    Eculizumab infusion treated for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with hemoglobin (Hb) level ≥ 120 g/L in at least 3 of 4 measurements between W18 and W24 in the absence of RBC transfusion (defined as no RBC transfusion after W2 through W24)Time frame: 24 weeks from Baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TianJin Medical University General Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.